The other strategy may apply tumor derived EVs as a potential glioma vaccination due to their ability to display tumor antigens that can activate DCs, which can then activate CD8+ T cells having antitumor potential (Fernández-Delgado et al., 2020). The gene discussed is CD8A; the disease is neoplasm.